Diaceutics Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BJQTGV64
GBP
1.44
-0.02 (-1.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROE of 0.95%

  • The company has been able to generate a Return on Equity (avg) of 0.95% signifying low profitability per unit of shareholders funds
2

Poor long term growth as Operating profit has grown by an annual rate -199.82% of over the last 5 years

 
3

The company has declared Negative results for the last 3 consecutive quarters

4

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 122 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.27

stock-summary
Return on Equity

-4.08%

stock-summary
Price to Book

3.28

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.06%
0%
12.06%
6 Months
-2.04%
0%
-2.04%
1 Year
13.83%
0%
13.83%
2 Years
41.87%
0%
41.87%
3 Years
39.13%
0%
39.13%
4 Years
43.28%
0%
43.28%
5 Years
26.87%
0%
26.87%

Diaceutics Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
19.07%
EBIT Growth (5y)
-199.82%
EBIT to Interest (avg)
-1.06
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.32
Sales to Capital Employed (avg)
0.53
Tax Ratio
10.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.74%
ROE (avg)
0.95%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.33
EV to EBIT
-51.09
EV to EBITDA
40.26
EV to Capital Employed
4.20
EV to Sales
3.31
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.22%
ROE (Latest)
-4.08%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Diaceutics Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 35.86% vs 21.54% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -342.86% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.20",
          "val2": "23.70",
          "chgp": "35.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.30",
          "val2": "2.10",
          "chgp": "9.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "-1.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-71.40%",
          "val2": "-114.70%",
          "chgp": "4.33%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
32.20
23.70
35.86%
Operating Profit (PBDIT) excl Other Income
2.30
2.10
9.52%
Interest
0.10
0.10
Exceptional Items
-0.50
0.00
Consolidate Net Profit
-1.70
-1.70
Operating Profit Margin (Excl OI)
-71.40%
-114.70%
4.33%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 35.86% vs 21.54% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 0.00% vs -342.86% in Dec 2023

stock-summaryCompany CV
About Diaceutics Plc stock-summary
stock-summary
Diaceutics Plc
Pharmaceuticals & Biotechnology
Diaceutics PLC is a United Kingdom-based data analytics and implementation services company which services the global pharmaceutical industry. The Company offers end to end services that encompasses from understanding the diagnostic landscape to test implementation into treatment pathways to enable better treatment decisions for patients. The Company’s data analytics and implementation services, including Landscape, Tracking, and Primary Market Research, leverages the diagnostic testing information to provide data-driven insights to drive seamless integration of diagnostic tests into treatment pathways. Its implementation services include Planning, Commercialization and Reimbursement Landscapes, to build the strategies and implement the tactics that drives optimal test utilization, ensuring that patients are getting the right treatment.
Company Coordinates stock-summary
Company Details
727 Antrim Road , BELFAST NIR : BT2 8FE
Registrar Details